BRPI0909183A2 - Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase - Google Patents
Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturaseInfo
- Publication number
- BRPI0909183A2 BRPI0909183A2 BRPI0909183-1A BRPI0909183A BRPI0909183A2 BR PI0909183 A2 BRPI0909183 A2 BR PI0909183A2 BR PI0909183 A BRPI0909183 A BR PI0909183A BR PI0909183 A2 BRPI0909183 A2 BR PI0909183A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treatment method
- coa desaturase
- condition treatment
- Prior art date
Links
- 229940123980 Desaturase inhibitor Drugs 0.000 title 1
- 108010087894 Fatty acid desaturases Proteins 0.000 title 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN575KO2008 | 2008-03-20 | ||
| US4948008P | 2008-05-01 | 2008-05-01 | |
| PCT/US2009/037835 WO2009117676A2 (en) | 2008-03-20 | 2009-03-20 | Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0909183A2 true BRPI0909183A2 (pt) | 2015-08-25 |
Family
ID=41089526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0909183-1A BRPI0909183A2 (pt) | 2008-03-20 | 2009-03-20 | Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8129376B2 (pt) |
| EP (1) | EP2268143A4 (pt) |
| JP (1) | JP2011518774A (pt) |
| KR (1) | KR20100134680A (pt) |
| CN (1) | CN102036558A (pt) |
| AU (1) | AU2009225441B2 (pt) |
| BR (1) | BRPI0909183A2 (pt) |
| CA (1) | CA2719000A1 (pt) |
| IL (1) | IL208232A0 (pt) |
| MX (1) | MX2010010241A (pt) |
| NZ (1) | NZ588633A (pt) |
| RU (1) | RU2010142937A (pt) |
| WO (1) | WO2009117676A2 (pt) |
| ZA (1) | ZA201007252B (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5374377B2 (ja) * | 2007-10-18 | 2013-12-25 | 武田薬品工業株式会社 | 複素環化合物 |
| US8642583B2 (en) | 2008-10-30 | 2014-02-04 | Janssen Pharmaceutica Nv | Serotonin receptor modulators |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| BR112013000925A2 (pt) | 2010-07-15 | 2020-12-01 | Bayer Intellectual Property Gmbh | compostos heterocíclicos como pesticidas |
| PT2707101T (pt) | 2011-05-12 | 2019-05-30 | Proteostasis Therapeutics Inc | Reguladores da proteostase |
| NO2686520T3 (pt) * | 2011-06-06 | 2018-03-17 | ||
| FR3000491B1 (fr) * | 2012-09-27 | 2015-08-28 | Univ Lille Ii Droit & Sante | Composes utilisables dans le traitement des infections mycobacteriennes |
| CN103772267A (zh) * | 2012-10-24 | 2014-05-07 | 常州化学研究所 | 一种二苯胺制备咔唑的方法 |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| CU24442B1 (es) | 2014-04-04 | 2019-09-04 | X Rx Inc | Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina |
| CN107205972A (zh) * | 2014-04-23 | 2017-09-26 | X-Rx股份有限公司 | 自分泌运动因子的取代的n‑(2‑(氨基)‑2‑氧代乙基)苯甲酰胺抑制剂及它们的制备和在治疗lpa‑依赖的或lpa‑介导的疾病中的用途 |
| US20160047307A1 (en) * | 2014-08-15 | 2016-02-18 | General Electric Company | Power train architectures with low-loss lubricant bearings and low-density materials |
| WO2016054560A1 (en) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| CN106432232A (zh) * | 2016-09-18 | 2017-02-22 | 苏州汉德创宏生化科技有限公司 | 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法 |
| ES2973850T3 (es) | 2016-09-20 | 2024-06-24 | Centre Leon Berard | Derivados del benzoimidazol como agentes anticancerígenos |
| CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CA3049010A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CN107663184A (zh) * | 2017-11-15 | 2018-02-06 | 上海皓伯化工科技有限公司 | 一种N‑Boc‑4‑羟基哌啶的合成方法 |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| JP2021522253A (ja) | 2018-04-25 | 2021-08-30 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| CA3097219A1 (en) | 2018-05-09 | 2019-11-14 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| KR20220007845A (ko) * | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| AU2020346814A1 (en) * | 2019-09-13 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | KDM inhibitors and uses thereof |
| CN110845396B (zh) * | 2019-11-07 | 2023-01-20 | 宿迁联盛科技股份有限公司 | 一种2,2,6,6-四甲基-4-哌啶胺类化合物的制备方法 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN117247347A (zh) * | 2023-09-15 | 2023-12-19 | 安徽昊帆生物有限公司 | N-Boc-4-氨基哌啶的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6659090A (en) | 1989-11-16 | 1991-06-13 | Warner-Lambert Company | Acat inhibitors |
| US5459151A (en) * | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
| EP0751926B1 (en) | 1994-03-25 | 2007-09-12 | Isotechnika,Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6987001B2 (en) | 2000-02-24 | 2006-01-17 | Xenon Pharmaceuticals Inc. | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| EP1322767B1 (en) | 2000-09-26 | 2008-07-23 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a stearoyl-coa desaturase-hscd5 |
| MXPA05008878A (es) * | 2003-02-21 | 2005-10-05 | Pfizer | Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso. |
| KR20050045927A (ko) * | 2003-11-12 | 2005-05-17 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| JP4787529B2 (ja) * | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | 医薬組成物 |
| CN101084212A (zh) * | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途 |
| CN101090724A (zh) * | 2004-09-20 | 2007-12-19 | 泽农医药公司 | 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物 |
| JP5149009B2 (ja) * | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 |
| US7842696B2 (en) * | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| KR20100125316A (ko) * | 2008-03-26 | 2010-11-30 | 다이이찌 산쿄 가부시키가이샤 | 하이드록시퀴녹살린카르복사마이드 유도체 |
-
2009
- 2009-03-20 WO PCT/US2009/037835 patent/WO2009117676A2/en not_active Ceased
- 2009-03-20 CA CA2719000A patent/CA2719000A1/en not_active Abandoned
- 2009-03-20 MX MX2010010241A patent/MX2010010241A/es active IP Right Grant
- 2009-03-20 JP JP2011500989A patent/JP2011518774A/ja active Pending
- 2009-03-20 KR KR1020107023415A patent/KR20100134680A/ko not_active Ceased
- 2009-03-20 AU AU2009225441A patent/AU2009225441B2/en not_active Expired - Fee Related
- 2009-03-20 EP EP09721822A patent/EP2268143A4/en not_active Withdrawn
- 2009-03-20 US US12/408,486 patent/US8129376B2/en not_active Expired - Fee Related
- 2009-03-20 CN CN2009801176982A patent/CN102036558A/zh active Pending
- 2009-03-20 NZ NZ588633A patent/NZ588633A/en not_active IP Right Cessation
- 2009-03-20 RU RU2010142937/04A patent/RU2010142937A/ru unknown
- 2009-03-20 BR BRPI0909183-1A patent/BRPI0909183A2/pt not_active IP Right Cessation
-
2010
- 2010-09-19 IL IL208232A patent/IL208232A0/en unknown
- 2010-10-11 ZA ZA2010/07252A patent/ZA201007252B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010142937A (ru) | 2012-04-27 |
| WO2009117676A2 (en) | 2009-09-24 |
| NZ588633A (en) | 2012-03-30 |
| CN102036558A (zh) | 2011-04-27 |
| ZA201007252B (en) | 2011-12-28 |
| AU2009225441A1 (en) | 2009-09-24 |
| EP2268143A2 (en) | 2011-01-05 |
| CA2719000A1 (en) | 2009-09-24 |
| AU2009225441B2 (en) | 2012-12-13 |
| KR20100134680A (ko) | 2010-12-23 |
| WO2009117676A3 (en) | 2010-01-07 |
| IL208232A0 (en) | 2010-12-30 |
| US8129376B2 (en) | 2012-03-06 |
| EP2268143A4 (en) | 2012-06-27 |
| US20090239810A1 (en) | 2009-09-24 |
| JP2011518774A (ja) | 2011-06-30 |
| MX2010010241A (es) | 2010-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0909183A2 (pt) | Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase | |
| BRPI0817897A2 (pt) | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac | |
| BRPI0920284A2 (pt) | composição e método | |
| EP2315220A4 (en) | REACTOR COMPONENT AND REACTOR | |
| BRPI0919575A2 (pt) | método, e, composição | |
| BRPI0920498A2 (pt) | método de tratamento de uma condição em um sujeito | |
| BRPI0914770A2 (pt) | anotação de conteúdo de página da web | |
| BRPI0923011A2 (pt) | método, e, produto de programa de computador | |
| PT1976506T (pt) | Extratos de plantas que contêm canabinoides como agentes neuroprotetores | |
| EP2456310A4 (en) | SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS | |
| ES2465478T8 (es) | Composiciones farmacéuticas que comprenden brivaracetam | |
| BRPI0822472A2 (pt) | Método, camundongo, e, composição | |
| BRPI1015030A2 (pt) | método de redução do conteúdo de compostos orgânicos voláteis solúveis em água presentes em um gás | |
| FI20070935L (fi) | Koostumus ja menetelmä puun käsittelemiseksi | |
| EP2463316A4 (en) | acrylate composition | |
| FI20085564L (fi) | Menetelmä puun suojaamiseksi | |
| BRPI0823238A2 (pt) | Composição, e, método | |
| FR2942407B1 (fr) | Procede de photomaquillage et composition de photomaquillage | |
| IL213228A (en) | Cutting fluid composition for wiresawing and a method of using same | |
| BRPI0822782A2 (pt) | composição farmacêutica que compreende rosuvastatina | |
| FI20060484L (fi) | Lannoiterae ja menetelmä sen valmistamiseksi | |
| BRPI0913511A2 (pt) | método, arranjo e produto de programa de computador para determinar um estado de uma caixa de engrenagem" | |
| EP2132251A4 (en) | COMPOSITION AND METHOD | |
| DK2331310T3 (da) | Imprægneringsanlæg og -fremgangsmåde | |
| BRPI0910262A2 (pt) | composição que compreende polióis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DAS PRIORIDADES IN 575/KOL/2008 DE 20/03/2008 E US 61/049,480 DE 01/05/2008, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDEREM AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DAS REFERIDAS PRIORIDADES, QUE POSSUEM DEPOSITANTES DIFERENTES DO DEPOSITANTE DA FASE NACIONAL. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: NAO CONHECIDA A PETICAO NO 020130064868 DE 24/07/2013, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO TEM FUNDAMENTACAO LEGAL. |